Antibody humanisation using machine learning: 2-3 business days

AI-based CDR-Grafting using human germline sequences Bioinformatics analysis: Identification of parental CDRs and framework regions (FRs) 3D structure model building Antibody Humanisation Design considering structure, CDR compatibility & stability while maximizing diversity to increase chances of success Sequence optimization: besides humanisation, several other key parameters are considered (developability, manufacturability, solubility/aggregation, stability, immunogenicity, affinity, chemical liabilities & toxicities, identification of critical substitutions including back mutations) Generation of up to 22 humanised and optimised sequences Delivery of a detailed report OPTIONAL: Immunogenicity risk prediction including possible mutations for mitigation Antibody sequence liability analysis including possible mutations for mitigation Antibody sequence developability analysis including possible mutations for improvement

With the detailed report and our advices, customer will choose and confirm the identity of antibody variants to be produced by transient recombinant expression in next step.

Variant production: 15 business days

High-throughput transient recombinant IgG expression & purification of above-generated sequences using MAX™ (MultimAbXpress™) platform based on proprietary XtenCHO-Race™ cells (up to 22 antibody sequences plus parental antibody sequence) Recombinant antibody QC: quantification by UV280, reduced SDS-PAGE, % purity evaluation

Variant analysis: 2-3 business days

ELISA of each above variant against antigen vs BSA control OPTIONAL: Best 3 variants and parental antibody tested in SPR/BLI (affinity/KD), SEC-HPLC (purity, monomers, aggregates), nanoDSF (thermostability), DLS (particle size distribution, aggregates)

Does the AI predict mutations that preserve affinity and specificity while reducing immunogenicity?

Yes. The AI designs mutations to keep binding (affinity/specificity) as close as possible to the original antibody.

Can the platform handle complex or atypical antibodies (e.g., long CDR-H3, VHHs)?

Yes. The platform can handle complex or atypical antibody formats, including VHH and other challenging variable-region designs.

What is the typical timeline from sequence submission to delivery of humanized candidates?

The typical timeline is 2 to 3 days for the sequences and about 3 weeks with variant production and thorough analysis.

Does your workflow include expression and binding validation of humanized versions?

Yes, variants are transiently expressed and purified, and binding/activity is assessed by ELISA.

Is developability profiling part of the workflow (stability, aggregation risk, liabilities)?

Yes, developability/aggregation/stability are included as parameters considered during sequence optimization, and optional modules exist for developability analysis and liability analysis. Experimentally, aggregation (SEC-HPLC/DLS) and thermostability (nanoDSF) are available as optional tests.

Is the process compatible with antibodies from hybridoma, phage display, or single B cell platforms?

Yes, our service is compatible with all antibody generation platforms.

How do you minimize developability or stability issues introduced during humanization?

By progressive germline-guided transformation (not one-shot grafting), AI-guided risk stratification of mutations (low/medium/high risk), and computational structural validation (VH/VL quaternary structure, RMSF, RMSD) so only variants with native-like paratope architecture advance. Sequence optimization also explicitly considers developability, stability, solubility/aggregation, manufacturability, liabilities, etc.

Do I retain full ownership of all humanized variants generated?

Yes, IP of AI-generated sequences belongs to the customer (no extra royalty or milestone payments).

Are there any licensing fees, model-use restrictions, or royalty obligations?

No extra royalty or milestone payments are required.

What deliverables are included (variant sequences, in silico scores, expression data, binding data)?

Detailed report (including generated sequences information, production yields & QCs, and ELISA results) Amino acid sequences of AI-generated variants Purified antibody samples of recombinant variants (if any left after QC/analysis) All IP rights

Can you support further engineering steps, such as affinity maturation or stability optimization?

Yes, lead candidates can be selected for further humanization and/or CDR sequence optimization to improve biophysical properties and manufacturability, and affinity maturation can be done via the AIxplore® Affinity platform.

Do you offer services for expression, developability screening, or stable cell line development?

Yes, we do offer all of these services: Antibody expression via our High-Throughput platform Developability screening (testing such as SEC-HPLC, nanoDSF, DLS, SEC-MALS…) Stable cell line development

AI-driven antibody humanization service

In silico antibody humanization guided by the critical eye of our bioinformatics experts

Success rate

Weeks saved on the project’s timeline

0€

No win no fee

0Bn

Sequences in our proprietary AI

Fast-track your project: Save 5 weeks with AI -powered antibody humanization

De-risk discovery

100% Success rate
Fully guaranteed service

Fast Timeline

3-4 weeks timeline
Save 5 weeks compared to classic humanization

Fully Custom

We adapt our analysis to your project
Pick and choose among our full set of characterization techniques
We offer solutions for all budgets

No IP constraint

IP free
No royalties
No milestone payments

Endless possibilities

All major antibody formats (IgG, scFv, Fab, VHH…)
Broad species compatibility
Animal health: From any source species → to any target species

Start Your Antibody Humanization Project

Beyond Sequence Humanization: Optimize Developability Early

- AI-based CDR-Grafting using human germline sequences
- Bioinformatics analysis: Identification of parental CDRs and framework regions (FRs)
- 3D structure model building
- Antibody Humanisation Design considering structure, CDR compatibility & stability while maximizing diversity to increase chances of success
- Sequence optimization: besides humanisation, several other key parameters are considered (developability, manufacturability, solubility/aggregation, stability, immunogenicity, affinity, chemical liabilities & toxicities, identification of critical substitutions including back mutations)
- Generation of up to 22 humanised and optimised sequences
- Delivery of a detailed report
- OPTIONAL:
  
  Immunogenicity risk prediction including possible mutations for mitigation
  
  Antibody sequence liability analysis including possible mutations for mitigation
  
  Antibody sequence developability analysis including possible mutations for improvement
- High-throughput transient recombinant IgG expression & purification of above-generated sequences using MAX™ (MultimAbXpress™) platform based on proprietary XtenCHO-Race™ cells (up to 22 antibody sequences plus parental antibody sequence)
- Recombinant antibody QC: quantification by UV280, reduced SDS-PAGE, % purity evaluation
- ELISA of each above variant against antigen vs BSA control
- OPTIONAL: Best 3 variants and parental antibody tested in SPR/BLI (affinity/KD), SEC-HPLC (purity, monomers, aggregates), nanoDSF (thermostability), DLS (particle size distribution, aggregates)

Contact our Experts

Deliverables

Detailed report including generated sequences information, production yields & QCs with ELISA

Amino acid sequences of AI-generated variants

Purified antibody samples of recombinant variants

Intellectual property of AI-generated sequences; no extra royalties or milestone payments

More Than AI: Expert Guidance Behind Every Recommendation

ProteoGenix’s Proprietary AI

Built on a dataset of ~10 billion sequences and continuously strengthened by ProteoGenix’s own complex antibody humanization projects, our proprietary AI helps you make better decisions from the earliest design stage. By combining large-scale sequence intelligence with real-world project learnings, it supports the selection of human frameworks and the prioritization of variants with stronger developability profiles, so you can move forward with a humanized antibody that preserves binding and function while reducing downstream risk.

Discuss your Humanization Project with us

Expert Guidance

Our bioinformatics experts review every AI output and translate it into clear, experience-driven recommendations before you move into production. They check the proposed frameworks and mutations, weigh trade-offs between “humanness,” liability risk and sequence integrity. The result is not just a list of candidates, but a practical decision package that helps you choose the best humanized formats, backed by both data and expert judgment.

Contact our Bioinformatics Experts

One single partner for your entire project with our integrated services

Custom antibody development from discovery to large scale production

Antibody Discovery

Antibody Affinity Maturation

Antibody humanization

Antibody Engineering

Recombinant Antibody Production

Stable Cell Line Development

Save time and resources with our AI-driven antibody services

AI-boosted Affinity Maturation

AI-Powered Developability

AI-driven Epitope & Paratope Mapping

FAQ

Yes, developability/aggregation/stability are included as parameters considered during sequence optimization, and optional modules exist for developability analysis and liability analysis. Experimentally, aggregation (SEC-HPLC/DLS) and thermostability (nanoDSF) are available as optional tests.
By progressive germline-guided transformation (not one-shot grafting), AI-guided risk stratification of mutations (low/medium/high risk), and computational structural validation (VH/VL quaternary structure, RMSF, RMSD) so only variants with native-like paratope architecture advance. Sequence optimization also explicitly considers developability, stability, solubility/aggregation, manufacturability, liabilities, etc.
- Detailed report (including generated sequences information, production yields & QCs, and ELISA results)
- Amino acid sequences of AI-generated variants
- Purified antibody samples of recombinant variants (if any left after QC/analysis)
- All IP rights
Yes, we do offer all of these services:
- Antibody expression via our High-Throughput platform
- Developability screening (testing such as SEC-HPLC, nanoDSF, DLS, SEC-MALS…)
- Stable cell line development

📢 -40% on Recombinant Antibody Production. Available until January 31, 2026 on your first order. Code: RECAB40

AI-driven antibody humanization service

In silico antibody humanization guided by the critical eye of our bioinformatics experts

Fast-track your project: Save 5 weeks with AI -powered antibody humanization

De-risk discovery

Fast Timeline

Fully Custom

No IP constraint

Endless possibilities

Beyond Sequence Humanization: Optimize Developability Early

Deliverables

Detailed report including generated sequences information, production yields & QCs with ELISA

Amino acid sequences of AI-generated variants

Purified antibody samples of recombinant variants

Intellectual property of AI-generated sequences; no extra royalties or milestone payments

More Than AI: Expert Guidance Behind Every Recommendation

ProteoGenix’s Proprietary AI

Expert Guidance

One single partner for your entire project with our integrated services

Custom antibody development from discovery to large scale production

Save time and resources with our AI-driven antibody services

FAQ

Need a quote or more information? Contact us!

Cart (0 Items)

📢 -40% on Recombinant Antibody Production. Available until January 31, 2026 on your first order. Code: RECAB40

AI-driven antibody humanization service

In silico antibody humanization guided by the critical eye of our bioinformatics experts

Fast-track your project: Save 5 weeks with AI -powered antibody humanization

De-risk discovery

Fast Timeline

Fully Custom

No IP constraint

Endless possibilities

Beyond Sequence Humanization: Optimize Developability Early

Step 1 Antibody humanisation using machine learning: 2-3 business days

Step 2 GO/NO-GO checkpoint

Step 3 Variant production: 15 business days

Step 4 Variant analysis: 2-3 business days

Deliverables

Detailed report including generated sequences information, production yields & QCs with ELISA

Amino acid sequences of AI-generated variants

Purified antibody samples of recombinant variants

Intellectual property of AI-generated sequences; no extra royalties or milestone payments

More Than AI: Expert Guidance Behind Every Recommendation

ProteoGenix’s Proprietary AI

Expert Guidance

One single partner for your entire project with our integrated services

Custom antibody development from discovery to large scale production

Save time and resources with our AI-driven antibody services

FAQ

Does the AI predict mutations that preserve affinity and specificity while reducing immunogenicity?

Can the platform handle complex or atypical antibodies (e.g., long CDR-H3, VHHs)?

What is the typical timeline from sequence submission to delivery of humanized candidates?

Does your workflow include expression and binding validation of humanized versions?

Is developability profiling part of the workflow (stability, aggregation risk, liabilities)?

Is the process compatible with antibodies from hybridoma, phage display, or single B cell platforms?

How do you minimize developability or stability issues introduced during humanization?

Do I retain full ownership of all humanized variants generated?

Are there any licensing fees, model-use restrictions, or royalty obligations?

What deliverables are included (variant sequences, in silico scores, expression data, binding data)?

Can you support further engineering steps, such as affinity maturation or stability optimization?

Do you offer services for expression, developability screening, or stable cell line development?

Need a quote or more information? Contact us!

Cart (0 Items)